Protagonist Therapeutics (PTGX) Consolidated Net Income (2015 - 2026)
Protagonist Therapeutics (PTGX) posted Consolidated Net Income of $3.8 million for Q1 2026, up 108.52% sequentially from -$44.4 million in Q4 2025, and up 132.46% YoY from $1.6 million in Q1 2025.
Protagonist Therapeutics (PTGX) Consolidated Net Income (2015 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Consolidated Net Income for 12 years, with the latest figure at $3.8 million in Q1 2026.
- Quarterly Consolidated Net Income rose 132.46% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$114.7 million (down 304.31% YoY) and the FY2025 annual result came in at -$130.1 million, down 147.3% from the prior year.
- Consolidated Net Income improved to $3.8 million in Q1 2026 per PTGX's latest filing, from -$44.4 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at $207.4 million in Q1 2024 and troughed at -$66.9 million in Q1 2022.
- A 5-year average of -$5.4 million and a median of -$33.7 million in 2023 frame the typical range for Consolidated Net Income.
- The sharpest annual moves came in 2022 and 2024: Consolidated Net Income tumbled 178.95% in 2022, then soared 714.87% in 2024.
- Over 5 years, Consolidated Net Income stood at -$34.9 million in 2022, then soared by 225.69% to $43.9 million in 2023, then jumped by 199.7% to $131.6 million in 2024, then sank by 133.72% to -$44.4 million in 2025, then surged by 108.52% to $3.8 million in 2026.
- According to Business Quant data, Consolidated Net Income over the past three periods registered $3.8 million, -$44.4 million, and -$39.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | 162.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 162.81 Mn |
| Mar 31, 2026 | 3.78 Mn |
| Dec 31, 2025 | -44.38 Mn |
| Sep 30, 2025 | -39.34 Mn |
| Jun 30, 2025 | -34.80 Mn |
| Mar 31, 2025 | -11.66 Mn |
| Dec 31, 2024 | 131.62 Mn |
| Sep 30, 2024 | -33.21 Mn |
| Jun 30, 2024 | -30.59 Mn |
| Mar 31, 2024 | 207.37 Mn |
| Dec 31, 2023 | 43.92 Mn |
| Sep 30, 2023 | -34.11 Mn |
| Jun 30, 2023 | -38.46 Mn |
| Mar 31, 2023 | -33.73 Mn |
| Dec 31, 2022 | -34.94 Mn |
| Sep 30, 2022 | -33.45 Mn |
| Jun 30, 2022 | -42.66 Mn |
| Mar 31, 2022 | -66.94 Mn |
| Dec 31, 2021 | -36.91 Mn |
| Sep 30, 2021 | -33.80 Mn |